{"id":732915,"date":"2023-02-21T07:33:51","date_gmt":"2023-02-21T12:33:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/"},"modified":"2023-02-21T07:33:51","modified_gmt":"2023-02-21T12:33:51","slug":"sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/","title":{"rendered":"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics"},"content":{"rendered":"<h2>\n&#8211; New crystal structure data supporting SNS-101 mechanism of action &#8211;<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Feb.  21, 2023  (GLOBE NEWSWIRE) &#8212; Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, presented preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, in an oral presentation at Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Keystone Symposia.<\/p>\n<p>\u201cPreclinical studies to date have demonstrated SNS-101\u2019s potential to significantly enhance the anti-tumor effects of PD-1 blockade while abrogating target-mediated drug disposition (TMDD) and with lower risk of cytokine release syndrome (CRS). New crystal structure analysis further elucidates the antibody\u2019s mechanism of action, showing that SNS-101 directly blocks the pH-dependent interaction between VISTA and PSGL-1,\u201d said Edward van der Horst, Ph.D., Chief Scientific Officer of Sensei Biotherapeutics. \u201cTogether, these preclinical data support the biological rationale for our pH-dependent approach, which we believe is key to targeting active protonated VISTA with exquisite selectivity.\u201d<\/p>\n<p>\n        <strong>Presentation highlights: <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>The epitope of SNS-101 was determined by co-crystallization of VISTA with the fragment antigen-binding domain of SNS-101. Crystal structure analysis suggests SNS-101 directly blocks the pH-dependent interaction between VISTA and PSGL-1, as well as interactions with other putative receptors.<\/li>\n<li>\n          <em>In vitro<\/em> and <em>in vivo<\/em> assays demonstrated that treatment with SNS-101 potentially has a significantly lower risk of inducing CRS than a non-pH-dependent VISTA antibody.<\/li>\n<li>SNS-101 exhibited linear elimination kinetics in non-human primates, overcoming TMDD-induced pharmacokinetic limitations observed with other anti-VISTA antibodies.<\/li>\n<li>SNS-101 induced expansion of na\u00efve and memory T-cell phenotypes <em>in vivo<\/em> without activation or depletion of monocytes, differentiating it from non-pH-selective antibodies.<\/li>\n<li>SNS-101 demonstrated significant enhancement of anti-tumor effects in combination with anti-PD-1 antibodies in syngeneic tumor models.<\/li>\n<\/ul>\n<p>Sensei expects to submit an Investigational New Drug (IND) application for SNS-101 in or before April 2023, with a Phase 1\/2 clinical trial expected to commence in 2023, pending regulatory clearance.<\/p>\n<p>A poster summarizing content from Dr. van der Horst\u2019s oral presentation will be on display at the conference during Poster Session 2, being held today, February 21, 2023, at 7:30 p.m. MST. The poster will be available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QBwGRtliImAmP96-fw0SkNb28GiCpVCJ2uTcs6E_a8mX79r_JR0N6P1FUweSWsX2mzd2mPxy6VYpwltceHKRNuVyBemezRhWLxfcakjVCdN_gghEVCCWFae9hlurew26\" rel=\"nofollow noopener\" target=\"_blank\">Sensei website<\/a> following the poster session.<\/p>\n<p>\n        <strong>About Sensei Biotherapeutics<\/strong><br \/>\n        <br \/>Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb\u2122 (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei\u2019s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NjKGvFdiphTvVArHPBfV_Fa__3KSlhZsvdzMJ56_v0OzI_jqzMqAHgSA6JnxzE6uclGhQ6grf4J9678RZHb29z5P33II7IGlDGzoGKIOZPrpDB7QqGkIWnNFX9RMZqC5xWAGBxmTu8dlYY8JHaeN15n3uJ04TBxDT0cljxyGa4nPkakbrlpflEnEI2326u1WdCN8KM2pcUilPaxox5dl016ZEVWK09bgPCkOwRLgppQlGYrV4cPYXeFj5DTvVqpu1CQ40tMVsIgXoPXu__PM9xDP53cU5S4TOzIWntEUzpWuq8BFw8tHQ0qbRqMe3vjGfouwix7iaDYLvmuWcsUnk685uL9FQ9vc3jgywBy8kNUOOI2SGnFHR8MYbkZlWOhE0LRrgdW1U7SVmidt-YQd8vk-ndflkzyJHGBruJ4bJtDzhMfHI0bLJw9rSG0WgxQbVEvdzHGH1fB3jlZmOR27q5I9vCsGvwYWOORV01-oS0iv7nK5V8DRV74bRKntFPgBxsq5JBzW_wD2EgIzIRotlBpX8cddO76pPoKJXRdO0fOvyEplp2d7aFYi7oIS_RiVOnsIQTnXIMUqbqwomSrDEH6zJQdEMMriDB_7CMupjy7m_cWgGoF_InzCOXHoQ976k_BaADccohgC2tFmo9XoD1Dpw7uOmc3NXDbD94jG67HHqQXdaaQkjoWVqv1YQ64p1ndQpi1yqrBDH9IMgpfd6A9QFZRjQ6MJkDV576gslx32jXyQgfh4EPZMpGwGwRo3RtVtvjprXDX_DwFbbp0syhRLqHNnmYyugPtTf0-6xY4rqu1tCkuy6bLxWt5m6wABNVCzVnO5QgGvk2N_TyYeGzyj3rCtQcoTY8Fq9RdLSxJtiqFwybect3eIntmap0KO2yAMN4kf0SabmH0jiBMod4kFa8X08yUnBuOQDUG0E4aDnq0bSqT0csAuaa4WBuLI5zvuB0VoQPjwwv_RJQfDk4hUVf7nhEpltVIyfYtlZUDu8zS4KOLvf5ryEHHmScrS\" rel=\"nofollow noopener\" target=\"_blank\">www.senseibio.com<\/a>, and follow the company on Twitter @SenseiBio and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a6LxwgxjZPIZVWt_1n56WkXsl7jV1XGbq4oFJxA38UTJQrKC-yN6bPZtFIQcxzeuN55Is354M2554Oj1x9ItJhSk8IhB6FaOhXMa28_hK6hhBH1td7kAJyFotF7S-6mFDeg7Rv-HsMAGNRoPBEWolTUOS4JmgaUSYYG64NmZ6SBY71vCTHioKtA1s83dHo-AYfccmGe4uavPa8iknBZkGPw7nPFbtTMUaI1t05ee9JfUCBY9Xv09VEwwRkzuhC31NjtLPfJ7T_ESjOlkuEKae2DdAtn53kGh7A60J1NwGT2Hz9cUnCLDQ_NunjLmwZVXSleVbdWNt4qACLyqC6poqgFFVfsGZHfxO4z87IgEjwzwLCY76FBg6XByRDi_gU-de2IwhlvpsUnBWvB76tCU-TvgTaiiDl8KhuAFIMZsAjgkqXyjBSLOL58En8Qh1qvqu6b9OxgtGeNKksQ2D1KPZ9CJ-BjNoRgLE_vCNJ8yYGUD4adImFs9fvzfE01DedLL3HeKGiNlR0j_qczBFIF94dQUnjcWWev1uOKR9ZieYvMADKa0Jd7VRdG8sx1JO7KeVTkzopMO7bf1XvsLmc7m4Fhkijdf-Q61dC78BDDJ5OEQvKFx3eg3-zmewgohjF2e6vghC1tGje2jtXMWtx9gLUBKbWfK-4ObbhamHtrqWbI3HonUzj2ZD4ExUIU8aj4p9D7jNEfGmMCzjEA-Rj_Yx8YrBBQiXiPtjeSD_59Ii6wZEDfSVObh3chDufKy7rs6ELh0aTrWzy_jA_-ifUyc0zkzEdhoMgYTFqwiLqK3Muym3ivOCXdZP1w5C1OhqDvarYVeyYpAIUmsYqSsRvAEz93GmeJZNxAKnU2XR6BKGC9QBoyYs0Tpc82GTBDNJKzLkH8iOuMAuQ6xD7pwEQgmSU-qiPBurJgFQ86COIVam3U5GsCrlYuwIsPyETJXnv7cHuypBFM1HRa4g-kTA2NxNWgSnIdTmdHQUDTT1IDE5F1-8Axi0xLB2P7gpDlSq4J7QRPZhl_-eI73uPjLKynk-w==\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as \u201cbelieve\u201d, \u201cdesigned to,\u201d \u201cexpect\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201cwill\u201d, and similar expressions, and are based on Sensei\u2019s current beliefs and expectations. These forward-looking statements include expectations regarding the development of Sensei\u2019s product candidates and platforms, including SNS-101; the potential safety profile of Sensei\u2019s product candidates, including SNS-101; the potential benefits of Sensei\u2019s product candidates, including SNS-101, including the potential to overcome pharmacokinetic and safety issues associated with targeting the VISTA immune checkpoint, including target-mediated drug disposition and cytokine release syndrome, as well as the potential to enhance anti-tumor effects in combination with anti-PD-1 antibodies. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei\u2019s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei\u2019s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies, including the preclinical studies described in this press release, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei\u2019s product candidates; the risk that Sensei\u2019s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate; risks associated with Sensei\u2019s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which we may not always have full control; risks regarding the accuracy of our estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei\u2019s Annual Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on November 8, 2022 and Sensei\u2019s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. <\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Michael Biega<br \/>Senior Director, Investor Relations<br \/>Sensei Biotherapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OqYvEVGRLAr2Wf5-ZhGMIEy-haKzACCD2jU-EOgexrlgot4m41OQOOAUtuhmawpXLZ3JcZdculB8HqwEw7hlRG2EFrE3mFW-cl332zf0n5zCF6xfETtZRrd-Ks4GwFfIMRciu-3JTZfj4f3s481XFLsP8enaLDMg2wYeyoT9vN_FHfS6ETkW2xzoizpZYMtlO4jttoBW3ogCtYHebch9PVUDIfTjb4aA0q-tQNFisrHKR_P4Q2Q8TM8iLqeb05SI93G-P3S7_-XHeQvq9MLFgw==\" rel=\"nofollow noopener\" target=\"_blank\">mbiega@senseibio.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Chris Railey<br \/>Ten Bridge Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1mPMWUDnYuODiz6ypr7TM78Zg-8RkZT1tziMW0e2axiN4Ztvb0V1JOe3oHxy6G2voSlOlBtn4GeuqNWHqNAi_EN1Vv4WbgZf3ECAAgOE9Bw8rnaK3pqagDVp3IhVzut41Sfh_II1SA7IowAtqllXuEZ2V05Y_u8uznWZ_OcFEu6eJaRYOM2dWAHDZvBNzVnod7x07VZZDpWwK1Lly_3ZQC-w-HKehiICibeVjKWctj89GwHiPWAcnexdIPobf00qZDjarSCNKxYjZ3l2k9w0ikV5IomWjtI6S9q6TXWyTKfwmYOtj38SXUNHc7cWBMaF\" rel=\"nofollow noopener\" target=\"_blank\">chris@tenbridgecommunications.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzE1NSM1NDIwMDkyIzIyMDQ0Nzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MmY5NjRkZDUtYjMzYi00MGEyLTg2NjctM2I3Y2E4MTk2NzAxLTEyMTYwMzA=\/tiny\/Sensei-Biotherapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; New crystal structure data supporting SNS-101 mechanism of action &#8211; BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, presented preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, in an oral presentation at Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Keystone Symposia. \u201cPreclinical studies to date have demonstrated SNS-101\u2019s potential to significantly enhance the anti-tumor effects of PD-1 blockade while abrogating target-mediated drug disposition (TMDD) and with lower risk of cytokine release syndrome (CRS). New crystal structure analysis further elucidates the antibody\u2019s mechanism of action, showing that SNS-101 directly blocks the pH-dependent interaction between VISTA and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-732915","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; New crystal structure data supporting SNS-101 mechanism of action &#8211; BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, presented preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, in an oral presentation at Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Keystone Symposia. \u201cPreclinical studies to date have demonstrated SNS-101\u2019s potential to significantly enhance the anti-tumor effects of PD-1 blockade while abrogating target-mediated drug disposition (TMDD) and with lower risk of cytokine release syndrome (CRS). New crystal structure analysis further elucidates the antibody\u2019s mechanism of action, showing that SNS-101 directly blocks the pH-dependent interaction between VISTA and &hellip; Continue reading &quot;Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-21T12:33:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzE1NSM1NDIwMDkyIzIyMDQ0Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics\",\"datePublished\":\"2023-02-21T12:33:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/\"},\"wordCount\":975,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzE1NSM1NDIwMDkyIzIyMDQ0Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/\",\"name\":\"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzE1NSM1NDIwMDkyIzIyMDQ0Nzc=\",\"datePublished\":\"2023-02-21T12:33:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzE1NSM1NDIwMDkyIzIyMDQ0Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzE1NSM1NDIwMDkyIzIyMDQ0Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics - Market Newsdesk","og_description":"&#8211; New crystal structure data supporting SNS-101 mechanism of action &#8211; BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, presented preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, in an oral presentation at Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Keystone Symposia. \u201cPreclinical studies to date have demonstrated SNS-101\u2019s potential to significantly enhance the anti-tumor effects of PD-1 blockade while abrogating target-mediated drug disposition (TMDD) and with lower risk of cytokine release syndrome (CRS). New crystal structure analysis further elucidates the antibody\u2019s mechanism of action, showing that SNS-101 directly blocks the pH-dependent interaction between VISTA and &hellip; Continue reading \"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-21T12:33:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzE1NSM1NDIwMDkyIzIyMDQ0Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics","datePublished":"2023-02-21T12:33:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/"},"wordCount":975,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzE1NSM1NDIwMDkyIzIyMDQ0Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/","name":"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzE1NSM1NDIwMDkyIzIyMDQ0Nzc=","datePublished":"2023-02-21T12:33:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzE1NSM1NDIwMDkyIzIyMDQ0Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzE1NSM1NDIwMDkyIzIyMDQ0Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-presents-preclinical-data-for-sns-101-a-conditionally-active-vista-blocking-antibody-at-the-keystone-symposia-on-next-generation-antibody-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=732915"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732915\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=732915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=732915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=732915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}